[Substitution therapy with alpha-1-Pi in patients with alpha-1-Pi deficiency and progressive pulmonary edema].
In a multi-centre study 20 patients with severe congenital alpha-1-Pi deficiency and progressive pulmonary emphysema received infusions of alpha-1-Pi concentrate from human plasma once weekly for six months, at an initial dosage of 60 mg/kg body-weight, in some instances slightly increased to achieve a minimum serum level above 70 mg/100 ml. The immunologically measured serum level of alpha-1-Pi rose 30 min after start of the infusion by a mean of 130% of normal, at an initial level of 13%. An exponential fall followed this rise. The lowest level occurred at the end of the first week, immediately before the next infusion, to 35% of normal, a serum level which is assumed still to provide an effective protection against elastases in the lung. There was also a definite increase of free inhibitors against both trypsin and leucocyte-elastase in serum of all patients, with a minimal level which for both was many times that of the initial value. There were no side-effects in more than 500 infusions and no dose reduction was necessary. During the entire course there were no significant changes in haematological, coagulation and biochemical test results, and lung function means remained constant. No antibodies against alpha-1-Pi were demonstrated, nor transmission of hepatitis B.
Konietzko
N
N
Zentrum für Pneumologie und Thoraxchirurgie, Medizinische Universitätsklinik, Krankenhaus Bergmannsheil, Bochum.
Becker
M
M
Schmidt
E W
EW
Rasche
B
B
Ulmer
W T
WT
Ferlinz
R
R
Lorenz
J
J
D002986:Clinical Trials as Topic; D006098:Granulocytes / Q000201:enzymology; D006801:Humans; D010196:Pancreatic Elastase / Q000097:blood; D010641:Phenotype; D011656:Pulmonary Emphysema / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000009:adverse effects / Q000032:analysis; D019896:alpha 1-Antitrypsin Deficiency
D000515:alpha 1-Antitrypsin; D010196:Pancreatic Elastase
Substitutionstherapie mit Alpha-1-Pi bei Patienten mit Alpha-1-Pi-Mangel und progredientem Lungenemphysem.